Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era

NCT00902434 | Completed

• 1 other identifier: 0903
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is an exploratory analysis that is investigating the pattern of care in patients over the age of 80 who were diagnosed with non-Hodgkin lymphoma (NHL). This study will look at the dose intensity and density implemented in this patient population to calculate whether patients received the full course of therapy, received less duration of treatment, or received lower doses of the drugs administered. Furthermore, the investigators would explore time to disease progression for these patients regardless of the treatment received and investigate whether patient outcomes differ based on the type of therapy or dose intensity/density given. This study is looking at retrospectively evaluating patients with NHL who are over the age of 80 at our institution between 2001-2007. It is anticipated that about 50 patients will be included in this study.

Conditions

Non-Hodgkin's Lymphoma

Keywords

Non-Hodgkin's Lymphoma

Eligibility Criteria

• Age: 80 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This study is looking at retrospectively evaluating patients with NHL who are over the age of 80 at our institution between 2001-2007.

You may qualify if:

• Patients with any NHL diagnosis regardless of histology who are over the age of 80 at the time of diagnosis will be included and analyzed.
• Data on age, gender, performance status, and major co-morbid conditions will be collected.
• Histology of the diagnosed NHL will be recorded. The grade (1, 2, or 3) for those who were diagnosed with follicular lymphoma will also be recorded.
• Stage of the disease, presence of bulky nodes and B symptoms will also be recorded.
• PET scan results if available.
• Type of treatment received will be recorded.
• Responses to therapy.
• Outcomes of treatment implemented and toxicities incurred.
• Subsequent therapies if applicable.

You may not qualify if:

• None. All charts of patients who are above the age of 80 at the time of NHL diagnosis will be analyzed.

Sponsors & Collaborators

• Oncology Specialists, S.C.: lead

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Chadi Nabhan, MD

  Oncology Specialists, S.C.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: May 14, 2009
• First Posted: May 15, 2009
• Study Start: May 1, 2009
• Primary Completion: February 1, 2011
• Study Completion: April 1, 2011
• Last Updated: July 1, 2014

Record last verified: 2014-06